School Of Basic And Applied Sciences

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/17

Browse

Subject: search.filters.subject.Drug delivery

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The creation of selenium nanoparticles decorated with troxerutin and their ability to adapt to the tumour microenvironment have therapeutic implications for triple-negative breast cancer
    (Royal Society of Chemistry, 2023-02-09T00:00:00) Saranya, Thiruvenkataswamy; Kavithaa, Krishnamoorthy; Paulpandi, Manickam; Ramya, Sennimalai; Winster, Sureshbabu Harysh; Mani, Geetha; Dhayalan, Sangeetha; Balachandar, Vellingiri; Narayanasamy, Arul
    Despite advancements in treatment, managing aggressive types of breast cancer, particularly Triple Negative Breast Cancer (TNBC), remains a daunting task. Newer chemotherapeutics enhance the multidrug resistance in cancer cells, making them untreatable. The current research work was framed to develop a novel therapeutic target by utilizing the flavanol, troxerutin (TXN) as a drug of interest to target TNBC. And also, to increase the efficiency of the drug at the target site, a nanocarrier called selenium nanoparticles (SeNPs) has been exploited. Thus, the anticancer efficacy of TXN and Se-TXN against TNBC (in vitro and in vivo) has been compared and analysed in the present study. Se-TXN was synthesized by a precipitation approach and characterized by diverse analytical techniques, which confirmed the successful loading of TXN on the SeNPs. The inhibitory concentration (IC50) of Se-TXN was determined to be 6.5 � 0.5 ?g mL?1 according to the in vitro data. Even at lower concentrations, the existence of apoptotic bodies shows that Se-TXN is effective against TNBC. Additionally, the Se-TXN expression study shows that the activation of the caspase cascade pathway, which results in apoptosis, occurs from the downregulation of anti-apoptotic proteins and genes and the upregulation of pro-apoptotic proteins and genes. And the in vivo investigations like histopathology, hematology and biochemical parameters revealed that the Se-TXN had significantly lowered the tumour volume of treated Balb/C mice without having any significant systemic toxicity when compared to other treatment groups. Altogether, our data suggests the efficacy of Se-TXN nanoconjugates as an effective management therapy for treating TNBC. � 2023 The Royal Society of Chemistry.
  • No Thumbnail Available
    Item
    Potential of Iron Oxide Nanoparticles as Drug Delivery Vehicle
    (Springer Science and Business Media Deutschland GmbH, 2021-10-29T00:00:00) Hassan, Muhammad Aamir; Khan, Aqib Zafar; Sajid, Muhammad Munir; Javed, Yasir; Ullah, Asmat; Shad, Naveed Akhtar; Sharma, Surender K.; Shafique, Muhammad; Sarwar, Muhammad
    Nanotechnology has introduced new techniques and therapeutic approaches for the treatment of different cancer types. Current cancer-curing drugs have many limitations such as use of high concentrations, effects on other cells, and non-confinement at cancer sites, which reduce the efficacy of drugs and also induce toxic effects in other normal cells. Nanomaterials have provided new ways to increase the efficacy of already used cancer drugs by providing drug delivery systems. Anticancer drugs can be encapsulated/attached with the nanomaterials and delivered at specific sites and cells under certain microenvironment conditions. Among metallic oxide nanoparticles, iron-based particles have shown great potential in drug delivery and at the same time for cancer treatment by producing localized heat. Therefore, researchers have focused on iron oxide nanoparticles as drug delivery vehicles. This chapter highlights the synthesizing methods of iron oxide nanoparticles such as co-precipitation, thermal decomposition, microemulsion, sol�gel, and additional chemical methods including hydrothermal, sonochemical decomposition, and electrochemical for their wide range of biomedical applications. It also provides a brief overview of recent developments in iron oxide nanoparticles, some limitations in the explored research areas. and suggests future directions to overcome these limitations. � 2021, Springer Nature Switzerland AG.
  • No Thumbnail Available
    Item
    Thioether linkage chemistry: perspectives and prospects in therapeutic designing
    (Elsevier, 2023-07-07T00:00:00) Singh, Yogesh; Kulkarni, Swanand; Thareja, Suresh
    Polymer�drug conjugates (PDCs) are an emerging approach for the development of targeted drug delivery systems for chemotherapeutic agents possessing poor pharmacokinetic properties. Development of PDCs offers an advantage of optimization to a certain extent to formulation as well as medicinal chemists via linking bioactive drug molecule to polymeric linker. Formulation of a drug in PDCs generally enhances the pharmacokinetic parameters of a drug by increasing its bioavailability. Also, controlled and target-specific drug release helps to reduce the adverse effects associated with off-target binding of the drugs. In this chapter, readers will be able to understand thoroughly the concept of PDCs, linkers used in the preparation of PDCs, their types, and various examples of PDCs that are reportedly found to be potent in the diseases they were intended to show activity. � 2023 Elsevier Inc. All rights reserved.